Breadcrumbs

Communique of GTTAC Meeting of 23 November 2016

This Communiqué covers matters considered at the 50th meeting of the Gene Technology Technical Advisory Committee (23 November 2016, Canberra).

Documents

Communique of GTTAC Meeting of 23 November 2016

This Communiqué covers matters considered at the 50th meeting of the Gene Technology Technical Advisory Committee (23 November 2016, Canberra).

Publication type:
Meeting communique
Publication date:
Description:

Sanofi-Aventis Australia Pty Ltd has applied for a licence for the import, transport, storage and disposal of a live genetically modified (GM) dengue vaccine, Dengvaxia, as part of its commercial supply in Australia. GTTAC noted that the Therapeutic Goods Administration has responsibility for assessing the quality, safety and efficacy of vaccines for use in humans in Australia. 

 

Last updated: